...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Transjecting growth hormone: continuous nightmare or controlled nuisance? Evaluation of a new needle-free device
【24h】

Transjecting growth hormone: continuous nightmare or controlled nuisance? Evaluation of a new needle-free device

机译：注射生长激素：持续的噩梦或可控的滋扰？评估新型无针装置

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Administering growth-hormone therapy (GHT) is a long-term treatment, associated with avoidance and phobic behaviors in the children involved. The current study examined GHT users’ perceptions of a new needle-free device (ZomaJet Vision X [10 mg/mL]) with a lower injection volume compared to the traditional device. Methods: A total of 73 persons participated (mean age ± standard deviation, 10.10 ± 3.60 years) in a longitudinal design. Users’ views were studied 4 weeks after having applied both the old and the new device for a period of at least 4 weeks. Satisfaction, ease and frequency of restitution, local sensations, bruises during administering GHT, affective response to local sensations, and subject preference were assessed on the basis of the users’ responses. Results: Subjects’ satisfaction with the new device was equal compared with the previous device for the total group of 73 children. However, the subgroup of 59 children who proved tolerant to meta-cresol (new preservative for Vision X only) reported a significantly higher satisfaction rating with the new device compared to the old device (7.7 vs 6.6, P=0.0002). Vision X was evaluated as better on ease and frequency of restitution and the number of bruises. Pain sensations did not differ meaningfully between the two devices. The new device was favored over the previous one in a majority of respondents. Vision X allows easy reconstitution of the solution, which was reflected in the percentage of young children able to prepare transjections themselves being more than doubled, illustrating the greater sense of empowerment in these users. Self-reported adherence to the therapy was good (less than 10% of injections missed) with both devices. Conclusion: The new device ZomaJet Vision X appears to be evaluated more positively than the previous version on criteria that reflect users’ preferences.
机译：背景：进行生长激素疗法（GHT）是一项长期治疗，与所涉儿童的回避行为和恐惧行为有关。当前的研究检查了GHT用户对新型无针设备（ZomaJet Vision X [10 mg / mL]）的看法，该设备的注射量低于传统设备。方法：总共73人参加了纵向设计（平均年龄±标准差，10.10±3.60岁）。在同时使用新旧设备至少4周后的4周内，研究了用户的观点。根据使用者的反应，评估其满意度，恢复的便利性和频率，局部感觉，GHT给药时的瘀伤，对局部感觉的情感反应以及受试者的偏爱。结果：在总共73名儿童中，受试者对新设备的满意度与之前的设备相同。但是，经证实耐受间甲酚（仅适用于Vision X的新型防腐剂）的59个儿童亚组报告说，与旧设备相比，新设备对新设备的满意度更高（7.7 vs 6.6，P = 0.0002）。 Vision X在恢复的容易程度和频率以及瘀伤的数量上被评估为更好。两种设备之间的疼痛感没有显着差异。在大多数受访者中，新设备比以前的设备受到青睐。 Vision X可以轻松地重新构造解决方案，这反映在能够自己准备弹射的幼儿的百分比增加了一倍以上，这说明这些用户具有更大的授权感。两种设备的自我报告的依从性均良好（漏诊率不到10％）。结论：新设备ZomaJet Vision X在反映用户喜好的标准上似乎比以前的版本得到更积极的评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号